辉大

HuidaGene Therapeutics is a global clinical-stage biotechnology company specializing in the development of novel genome-editing therapies for life-threatening diseases. Founded in 2018, the company leverages its proprietary HG-PRECISE® platform to discover and engineer high-fidelity CRISPR Cas12 and Cas13 systems. Their approach focuses on creating one-time curative treatments for genetic disorders across ophthalmology, neurology, and otology. The company's lead program, HG004, is currently in Phase 1/2 clinical trials for RPE65-associated retinal degeneration. HuidaGene maintains a robust internal manufacturing capability with a GMP facility in Shanghai to support its clinical pipeline. With operations in both China and the United States, the company is positioned as a leader in the next generation of genomic medicine.